David A. Siegel Meira G Tx Holdings PLC Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.8 - $8.98 $103,820 - $160,742	17,900 New	17,900 $116,000
Q2 2022 Aug 15, 2022	SELL	$6.8 - $14.23 $11,560 - $24,191	-1,700 Reduced 10.9%	13,900 $105,000
Q1 2022 May 16, 2022	BUY	$13.42 - $23.38 $209,352 - $364,728	15,600 New	15,600 $216,000
Q2 2021 Aug 16, 2021	SELL	$12.85 - $16.2 $151,630 - $191,160	-11,800 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$13.84 - $17.8 $190,992 - $245,640	-13,800 Reduced 53.91%	11,800 $170,000
Q4 2020 Feb 16, 2021	SELL	$12.4 - $17.6 $54,560 - $77,440	-4,400 Reduced 14.67%	25,600 $388,000
Q3 2020 Nov 16, 2020	SELL	$11.59 - $14.93 $168,055 - $216,485	-14,500 Reduced 32.58%	30,000 $397,000
Q2 2020 Aug 14, 2020	SELL	$11.79 - $15.97 $10,611 - $14,373	-900 Reduced 1.98%	44,500 $557,000
Q1 2020 May 15, 2020	SELL	$9.31 - $21.24 $13,034 - $29,735	-1,400 Reduced 2.99%	45,400 $610,000
Q4 2019 Feb 14, 2020	BUY	$13.91 - $21.48 $319,930 - $494,040	23,000 Added 96.64%	46,800 $937,000
Q3 2019 Nov 14, 2019	BUY	$15.84 - $30.01 $376,992 - $714,238	23,800 New	23,800 $380,000

100

45.4M

19.2K

31K

Ticker MGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,010,700
Market Cap $292M
Description
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative dise...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.